Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the three months ended March 31, 2018. The request identifies Imunon, Inc., but the filing itself is for Celsion Corporation. Celsion describes itself as a development-stage oncology drug company, with ThermoDox in a Phase III liver-cancer trial and GEN-1 in development for ovarian and brain cancers. It reported no product revenue.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Licensing revenue | $125,000 | $125,000 |
| Research and development | $2.74 million | $3.48 million |
| General and administrative | $1.67 million | $1.47 million |
| Operating loss | $4.28 million | $4.82 million |
| Net loss | $4.48 million | $5.16 million |
| Net loss per share, basic and diluted | $0.25 | $3.09 |
| Operating cash flow | $(4.66) million | $(3.13) million |
At March 31, 2018, cash and cash equivalents were $2.29 million and short-term investments were $18.41 million; including accrued investment interest, these resources totaled about $20.8 million. Current assets were $20.85 million, current liabilities $5.63 million, and working capital $15.22 million. Total liabilities were $20.39 million, including a $12.81 million EGEN earn-out milestone liability. The filing reports no outstanding note payable; the former Hercules loan had been repaid in 2017.
Cash fell by $9.16 million during the quarter, mainly reflecting operating cash use and $5.71 million of investment-security purchases, partly offset by $1.24 million of net ATM equity proceeds. The company reported an accumulated deficit of $266.26 million. Gross margin is not meaningful to assess from the filing because revenue was limited to licensing revenue and no product sales were reported.
Material changes versus the prior comparable period
Net loss narrowed by $0.68 million, while operating expenses fell $0.54 million. R&D declined $0.73 million, primarily due to lower OPTIMA and other clinical costs; G&A rose $0.20 million, including higher professional fees and compensation. Investment income increased to $73,724 from $1,991, while prior-year interest expense of $62,340 did not recur. The weighted-average share count rose to 17.68 million from 1.67 million; the filing notes a 14-for-1 reverse stock split in 2017, so the reported per-share comparison is not directly indicative of the change in aggregate losses.
Compared with December 31, 2017, total assets decreased from $47.51 million to $44.00 million, and working capital decreased from $18.11 million to $15.22 million. Cash and cash equivalents fell substantially, while short-term investments increased.
Outlook, management commentary, and risks
- Management estimated that available cash, investments and interest receivable would fund operations into the third quarter of 2019. It also said additional funding would be required to continue development and operations; approximately $12.2 million remained available under the Cantor ATM facility at quarter-end.
- The OPTIMA Phase III study’s independent monitoring committee completed its last scheduled review of data for the first 75% of randomized patients and recommended continuing the study to final readout. This was a continuation recommendation, not a finding of efficacy.
- Management expected to begin enrollment in the GEN-1 Phase I/II OVATION II study in Q2 2018. Reported OVATION I results were from a small early-stage study and should not be treated as confirmatory evidence of efficacy.
- The company expects operating losses to continue and has no assurance of achieving regulatory approval, commercialization or profitability. It may need further equity, debt or partnership financing; equity issuance may dilute existing holders, and inadequate funding could delay, reduce or end development programs.
- ThermoDox failed to meet the primary endpoint in the earlier Phase III HEAT study. Management’s support for OPTIMA includes retrospective subgroup analyses of HEAT data, which the filing cautions should be viewed carefully.
- Other material risks include clinical-trial and regulatory uncertainty, reliance on third-party trial and manufacturing providers, competition, intellectual-property and licensing risks, and volatility or dilution from outstanding warrants and future financings. The EGEN earn-out liability is based on fair-value estimates and may change with milestone expectations.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Celsion Corporation’s Q1 2018 10-Q, not a filing under the name Imunon, Inc.
- Track OPTIMA enrollment, data quality, safety updates and eventual final results; the DMC recommendation did not establish that the trial would succeed.
- Assess the cash runway against actual operating cash use, clinical-trial spending and the timing and terms of any new financing.
- Review potential dilution from ATM sales, warrants, options and any earn-out consideration; reported shares outstanding were 17,740,035 as of May 10, 2018.
- Monitor GEN-1 OVATION II launch and enrollment, and distinguish early-study findings from results in a larger randomized trial.
- Check future changes in the $12.81 million earn-out liability and any developments affecting the EGEN milestone obligations.